Dyson Paul J, Banat Ibrahim M, Quinn Gerry A
Medical School, Institute of Life Sciences, Swansea University, Swansea, United Kingdom.
Centre for Molecular Biosciences, Ulster University, Coleraine, United Kingdom.
Front Pharmacol. 2025 Jan 7;15:1504901. doi: 10.3389/fphar.2024.1504901. eCollection 2024.
The WHO has compiled a list of pathogens that urgently require new antibiotics in response to the rising reports of antibiotic resistance and a diminished supply of new antibiotics. At the top of this list is fluoroquinolone-resistant , fluoroquinolone-resistant spp. and vancomycin-resistant . Although these problems have been covered in great detail by other contemporary reviews, there are still some fundamental gaps in the translation of current knowledge of the infectious process and the molecular ecology of antibiotic production into a sustainable protocol for the treatment of pathogenic diseases. Therefore, in this narrative review we briefly discuss newly approved antimicrobial drugs (since 2014) that could help to alleviate the burden of multiresistant pathogens listed on the WHO priority list. Being conscious that such treatments may eventually run the risk of future cycles of resistance, we also discuss how new understandings in the molecular ecology of antibiotic production and the disease process can be harnessed to create a more sustainable solution for the treatment of pathogenic diseases.
鉴于抗生素耐药性报告不断增加且新抗生素供应减少，世界卫生组织（WHO）编制了一份急需新型抗生素的病原体清单。清单首位是耐氟喹诺酮的[具体菌名未给出]、耐氟喹诺酮的[具体菌名未给出]以及耐万古霉素的[具体菌名未给出]。尽管其他当代综述已对这些问题进行了详细阐述，但在将当前感染过程知识和抗生素生产分子生态学转化为治疗致病性疾病的可持续方案方面，仍存在一些根本性差距。因此，在本叙述性综述中，我们简要讨论自2014年以来新批准的抗菌药物，这些药物可能有助于减轻世界卫生组织优先清单上多重耐药病原体的负担。鉴于此类治疗最终可能面临未来耐药循环的风险，我们还将讨论如何利用抗生素生产分子生态学和疾病过程的新认识，为致病性疾病的治疗创造更可持续的解决方案。
